Once-daily Roclatan meets clinical endpoints in phase 2b trial

Aerie Pharmaceuticals’ once-daily glaucoma eye drop, Roclatan, met all clinical endpoints in its phase 2b trial, according to a company press release.The agent is a combination of the company’s triple-action Rhopressa — a once-daily eye drop targeting the trabecular meshwork — with latanoprost, a prostaglandin analogue.

Full Story →